Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29300337
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29300337
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Biomolecules
2018 ; 8
(1
): ä Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Emerging Roles for VEGF-D in Human Disease
#MMPMID29300337
Stacker SA
; Achen MG
Biomolecules
2018[Jan]; 8
(1
): ä PMID29300337
show ga
Blood vessels and lymphatic vessels are located in many tissues and organs
throughout the body, and play important roles in a wide variety of prevalent
diseases in humans. Vascular endothelial growth factor-D (VEGF-D) is a secreted
protein that can promote the remodeling of blood vessels and lymphatics in
development and disease. Recent fundamental and translational studies have
provided insight into the molecular mechanisms by which VEGF-D exerts its effects
in human disease. Hence this protein is now of interest as a therapeutic and/or
diagnostic target, or as a potential therapeutic agent, in a diversity of
indications in cardiovascular medicine, cancer and the devastating pulmonary
condition lymphangioleiomyomatosis. This has led to clinical trial programs to
assess the effect of targeting VEGF-D signaling pathways, or delivering VEGF-D,
in angina, cancer and ocular indications. This review summarizes our
understanding of VEGF-D signaling in human disease, which is largely based on
animal disease models and clinicopathological studies, and provides information
about the outcomes of recent clinical trials testing agonists or antagonists of
VEGF-D signaling.
free
free
free
